analyst day recap focu new product
acceler capit deploy
remain stabl compani core
attend wat analyst day first sinc ceo cfo
still rel new way noth chang remain product-
market-focus compani serv total address market roughli
sale come recur high margin consum servic typic
contribut organ sale growth qtr metric strong
there limit margin upsid current level gross oper
emphasi innov capit deploy
focu meet increas last
yr product innov shown number upcom new product alon
includ recent unveil bioaccord intrigu new
water connect laboratori informat platform integr wat empow cd
informat product one system greater flexibl capit
deploy wake us tax reform made ex-u cash access
acceler share buy-back on-going management repeatedli mention desir
strateg albeit big help fill analyt tool kit said
wat yr financi target organ sale growth flattish gross
modestli higher oper margin mid-teen tax rate double-digit ep growth
line expect consensu view key
core growth closer go forward given life scienc tool
peer agil thermo fisher track higher end
rang much opportun margin expans wat new
strategi also play key role
tweak organ sale est higher rais po
rais organ revenu forecast bps/yr
respect ep increas expect gain new
product mani still earli need independ custom feedback
yet rais po base
ep estimate multipl still line peer group multipl recent
expand reiter neutral rate await feedback new product
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
corp lead supplier
analyt instrument consum
product use mainli research
qualiti assur applic pharmaceut
life scienc biochem industri academ
govern custom compani
posit liquid chromatographi market
busi posit
mass spectrometri market
posit thermal analysi market
water face difficult market condit
product cycl share shift market
expect continu soft perform
near-term believ dynam take
time play expect compani
benefit share buyback low expect
easi comp
po base ep estim in-lin
compani lst peer group modest premium compani averag two year
histor multipl past five year due potenti new product cycl
back dcf analysi assum wacc termin growth rate
slow china tariff/trad war escal slower expect capit
deploy weaker global economi share loss competitor failur new
product deliv slowdown pharma biotech spend downsid risk
price object
upsid risk po faster expect capit deploy faster
expect uptak new product acquisit compani
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
qualiti earn
